NGM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 35.90%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

NGM Biopharmaceuticals Insider Trading History Chart

NGM Biopharmaceuticals Share Price & Price History

^$1.54

+0.30 (1.20%)

As of 04/5/2024 01:00 AM ET

NGM Biopharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/30/2023	Group L P Column	Director	Buy	7,542	$5.00	$37,710.00	750,501
1/23/2023	Group L P Column	Director	Buy	9,900	$5.00	$49,500.00	742,959
1/19/2023	Group L P Column	Director	Buy	37,639	$5.00	$188,195.00	732,559
1/17/2023	Jin-Long Chen	Insider	Sell	85,082	$5.15	$438,172.30	908,893
1/12/2023	Group L P Column	Director	Buy	5,378	$4.95	$26,621.10	694,920
1/10/2023	Group L P Column	Director	Buy	100,070	$4.84	$484,338.80	480,542
12/12/2022	Group L P Column	Director	Buy	300	$4.98	$1,494.00	380,472
11/21/2022	Group L P Column	Director	Buy	35,997	$5.00	$179,985.00	375,842
11/3/2022	Group L P Column	Director	Buy	104,090	$4.99	$519,409.10	304,787
10/27/2022	David V Goeddel	Director	Buy	76,877	$4.86	$373,622.22	200,697
10/25/2022	Group L P Column	Director	Buy	51,046	$4.75	$242,468.50	51,046
10/17/2022	David V Goeddel	Director	Buy	50,000	$3.18	$159,000.00	130,000
6/9/2022	Group L P Column	Director	Buy	984,161	$13.50	$13,286,173.50	2,650,177
6/2/2022	Group L P Column	Director	Buy	34,200	$13.03	$445,626.00	1,698,493
5/31/2022	Group L P Column	Director	Buy	61,806	$13.47	$832,526.82	1,576,458
5/26/2022	Group L P Column	Director	Buy	20,201	$13.49	$272,511.49	1,514,071
5/24/2022	Group L P Column	Director	Buy	17,828	$13.37	$238,360.36	1,452,674
5/19/2022	Group L P Column	Director	Buy	20,666	$13.25	$273,824.50	1,417,028
5/17/2022	Group L P Column	Director	Buy	89,049	$13.42	$1,195,037.58	1,336,461
5/11/2022	Group L P Column	Director	Buy	83,175	$11.25	$935,718.75	1,012,753
5/9/2022	Group L P Column	Director	Buy	83,175	$10.79	$897,458.25	902,090

See Full Table

SEC Filings (Institutional Ownership Changes) for NGM Biopharmaceuticals (NASDAQ:NGM)

75.74% of NGM Biopharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

NGM Biopharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/20/2024	Virtu Financial LLC	48,708	$77K	0.0%	N/A	0.058%
5/14/2024	Natixis	181,366	$0.29M	0.0%	N/A	0.217%
5/10/2024	Vanguard Group Inc.	2,324,392	$3.70M	0.0%	-16.1%	2.785%
5/1/2024	BNP Paribas Financial Markets	171,397	$0.27M	0.0%	-22.3%	0.205%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	21,169	$34K	0.0%	N/A	0.025%
2/5/2024	Russell Investments Group Ltd.	43,598	$37K	0.0%	-64.9%	0.053%
1/31/2024	Federated Hermes Inc.	345,381	$0.30M	0.0%	-41.0%	0.418%
1/30/2024	Mackenzie Financial Corp	62,964	$54K	0.0%	+40.3%	0.076%
1/5/2024	Exchange Traded Concepts LLC	107,019	$92K	0.0%	+34.0%	0.129%
12/1/2023	Euclidean Capital LLC	992,168	$1.06M	0.2%	+32.9%	1.199%
11/14/2023	Jasper Ridge Partners L.P.	303,492	$0.33M	0.0%	-12.9%	0.367%
11/14/2023	Pale Fire Capital SE	33,800	$36K	0.0%	N/A	0.041%
11/13/2023	Algert Global LLC	37,390	$40K	0.0%	-72.8%	0.045%
11/13/2023	Acadian Asset Management LLC	1,193,971	$1.28M	0.0%	+4.8%	1.443%
10/25/2023	Mackenzie Financial Corp	44,880	$48K	0.0%	+135.1%	0.054%
10/18/2023	Exchange Traded Concepts LLC	79,882	$85K	0.0%	+100.6%	0.097%
8/14/2023	Prelude Capital Management LLC	10,416	$27K	0.0%	N/A	0.013%
8/7/2023	Acadian Asset Management LLC	1,138,843	$2.95M	0.0%	+21.4%	1.383%
8/3/2023	Mackenzie Financial Corp	19,092	$52K	0.0%	+49.4%	0.023%
8/1/2023	Arizona State Retirement System	12,676	$33K	0.0%	N/A	0.015%
7/25/2023	Raymond James Financial Services Advisors Inc.	13,335	$35K	0.0%	-62.3%	0.016%
7/25/2023	Raymond James & Associates	22,233	$58K	0.0%	-22.2%	0.027%
7/20/2023	Exchange Traded Concepts LLC	39,816	$0.10M	0.0%	N/A	0.048%
7/19/2023	Teacher Retirement System of Texas	12,193	$32K	0.0%	N/A	0.015%
5/12/2023	Grantham Mayo Van Otterloo & Co. LLC	26,300	$0.11M	0.0%	N/A	0.032%
5/11/2023	Acadian Asset Management LLC	938,434	$3.82M	0.0%	+61.5%	1.139%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	194,151	$0.79M	0.0%	+25.7%	0.236%
5/8/2023	Federated Hermes Inc.	173,388	$0.71M	0.0%	N/A	0.211%
5/3/2023	Jump Financial LLC	36,400	$0.15M	0.0%	N/A	0.044%
4/28/2023	SG Americas Securities LLC	21,460	$88K	0.0%	+49.3%	0.026%
4/24/2023	Mackenzie Financial Corp	12,783	$52K	0.0%	N/A	0.016%
4/14/2023	Raymond James Financial Services Advisors Inc.	35,407	$0.14M	0.0%	-33.7%	0.043%
2/14/2023	Parkwood LLC	68,314	$0.34M	0.1%	+54.2%	0.084%
2/14/2023	Alpine Global Management LLC	17,765	$89K	0.0%	N/A	0.022%
2/14/2023	EcoR1 Capital LLC	6,435,518	$32.31M	1.0%	+1,089.3%	7.874%
2/13/2023	GSA Capital Partners LLP	129,279	$0.65M	0.1%	+1,069.0%	0.158%
2/13/2023	Cornercap Investment Counsel Inc.	46,062	$0.23M	0.0%	+300.6%	0.056%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	154,410	$0.78M	0.0%	+39.5%	0.189%
2/9/2023	Landscape Capital Management L.L.C.	21,492	$0.11M	0.0%	N/A	0.026%
2/8/2023	Raymond James Financial Services Advisors Inc.	53,427	$0.27M	0.0%	-37.1%	0.065%
2/8/2023	Russell Investments Group Ltd.	45,686	$0.23M	0.0%	+87.8%	0.056%
2/7/2023	Fox Run Management L.L.C.	45,798	$0.23M	0.1%	+300.1%	0.056%
2/2/2023	SG Americas Securities LLC	14,374	$72K	0.0%	+35.1%	0.018%
2/1/2023	Zurcher Kantonalbank Zurich Cantonalbank	11,516	$58K	0.0%	+43.2%	0.014%
1/17/2023	Diversified Trust Co	12,885	$65K	0.0%	N/A	0.016%
1/12/2023	Hennion & Walsh Asset Management Inc.	58,869	$0.30M	0.0%	-66.4%	0.072%
11/15/2022	Logos Global Management LP	850,000	$11.12M	1.4%	N/A	1.040%
11/15/2022	First Light Asset Management LLC	955,505	$12.50M	1.3%	-15.9%	1.169%
11/14/2022	Point72 Asset Management L.P.	362,900	$4.75M	0.0%	-72.5%	0.444%
11/14/2022	Cubist Systematic Strategies LLC	74,998	$0.98M	0.0%	-58.8%	0.092%
11/14/2022	PDT Partners LLC	34,267	$0.45M	0.1%	N/A	0.042%
11/14/2022	Nuveen Asset Management LLC	738,810	$9.66M	0.0%	+38.0%	0.904%
11/14/2022	Parkwood LLC	44,314	$0.58M	0.1%	N/A	0.054%
11/14/2022	AXA S.A.	405,683	$5.31M	0.0%	+0.8%	0.496%
11/14/2022	Rubric Capital Management LP	877,161	$11.47M	0.6%	+10.0%	1.073%
11/14/2022	Hsbc Holdings PLC	12,757	$0.17M	0.0%	+23.6%	0.016%
11/14/2022	Hennion & Walsh Asset Management Inc.	175,183	$2.29M	0.2%	+3.5%	0.214%
11/10/2022	Connor Clark & Lunn Investment Management Ltd.	110,699	$1.45M	0.0%	+207.0%	0.135%
11/10/2022	ExodusPoint Capital Management LP	52,672	$0.69M	0.0%	N/A	0.064%
11/8/2022	New York State Common Retirement Fund	26,462	$0.35M	0.0%	+16.5%	0.033%
11/7/2022	Jump Financial LLC	31,400	$0.41M	0.0%	+9.8%	0.039%
11/4/2022	Russell Investments Group Ltd.	24,332	$0.32M	0.0%	+94.7%	0.030%
11/3/2022	Barclays PLC	43,895	$0.58M	0.0%	+72.6%	0.055%
11/2/2022	Los Angeles Capital Management LLC	11,919	$0.16M	0.0%	N/A	0.015%
11/1/2022	Jennison Associates LLC	122,430	$1.60M	0.0%	N/A	0.152%
10/28/2022	Silverarc Capital Management LLC	94,517	$1.24M	0.4%	+7.0%	0.118%
10/27/2022	Strs Ohio	45,100	$0.59M	0.0%	-4.4%	0.056%
10/25/2022	Raymond James & Associates	95,686	$1.25M	0.0%	+34.8%	0.119%
10/25/2022	Raymond James Financial Services Advisors Inc.	84,886	$1.11M	0.0%	+35.4%	0.106%
9/2/2022	Amundi	7,407	$0.12M	0.0%	N/A	0.009%
8/16/2022	Woodline Partners LP	134,188	$1.72M	0.0%	-71.5%	0.167%
8/15/2022	Point72 Asset Management L.P.	1,320,662	$16.93M	0.1%	-58.9%	1.643%
8/15/2022	Partners Group Holding AG	177,255	$2.27M	0.1%	N/A	0.221%
8/13/2022	Column Group LLC	18,136,735	$232.51M	49.5%	+11.6%	22.568%
8/12/2022	First Light Asset Management LLC	1,135,884	$14.56M	1.7%	+39.1%	1.413%
8/12/2022	Lexington Partners L.P.	110,428	$1.42M	0.7%	N/A	0.137%
8/12/2022	Fox Run Management L.L.C.	11,128	$0.14M	0.1%	N/A	0.014%
8/11/2022	Deutsche Bank AG	263,912	$3.38M	0.0%	+53.5%	0.328%
8/11/2022	Washington University	44,314	$0.57M	0.2%	N/A	0.055%
8/11/2022	JPMorgan Chase & Co.	552,541	$7.08M	0.0%	+3.5%	0.687%
8/9/2022	Swiss National Bank	64,000	$0.82M	0.0%	-12.9%	0.080%
8/5/2022	State Board of Administration of Florida Retirement System	15,654	$0.20M	0.0%	N/A	0.020%
8/5/2022	Connor Clark & Lunn Investment Management Ltd.	36,053	$0.46M	0.0%	N/A	0.045%
8/4/2022	Steward Partners Investment Advisory LLC	4,817	$62K	0.0%	+138.8%	0.006%
8/1/2022	ProShare Advisors LLC	10,576	$0.14M	0.0%	-24.2%	0.013%
7/29/2022	SG Americas Securities LLC	11,719	$0.15M	0.0%	-79.9%	0.015%
7/29/2022	Russell Investments Group Ltd.	12,500	$0.16M	0.0%	-22.8%	0.016%
7/28/2022	Hamilton Lane Advisors LLC	37,503	$0.48M	0.2%	N/A	0.047%
7/26/2022	Mirae Asset Global Investments Co. Ltd.	10,974	$0.14M	0.0%	N/A	0.014%
7/25/2022	Silverarc Capital Management LLC	88,303	$1.13M	0.3%	-56.0%	0.111%
7/25/2022	Strs Ohio	47,200	$0.61M	0.0%	+5.1%	0.060%
7/19/2022	Hennion & Walsh Asset Management Inc.	169,337	$2.17M	0.1%	-31.3%	0.214%
6/30/2022	Amalgamated Bank	3,933	$60K	0.0%	N/A	0.005%
5/5/2022	Russell Investments Group Ltd.	16,183	$0.25M	0.0%	-21.5%	0.021%
5/2/2022	Steward Partners Investment Advisory LLC	2,017	$31K	0.0%	N/A	0.003%
4/29/2022	SG Americas Securities LLC	58,160	$0.89M	0.0%	-23.1%	0.074%
4/28/2022	DekaBank Deutsche Girozentrale	25,700	$0.40M	0.0%	+9.8%	0.033%
4/26/2022	Hennion & Walsh Asset Management Inc.	246,322	$3.76M	0.2%	-4.1%	0.315%
4/21/2022	Zurcher Kantonalbank Zurich Cantonalbank	8,040	$0.12M	0.0%	-19.3%	0.010%
2/14/2022	PDT Partners LLC	57,546	$1.02M	0.1%	+6.1%	0.074%

Data available starting January 2016

See Full Table

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.54

$1.54

50 Day Range

MA: $1.55

$1.52

$1.63

52 Week Range

Now: $1.54

$0.60

$4.69

Volume

N/A

Average Volume

1,467,160 shs

Market Capitalization

$128.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27